Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Clinical trial NCT07211178 · RECRUITING

Trial details

NCT number: NCT07211178
Sponsor: Tempus AI
Status: RECRUITING
Study type: OBSERVATIONAL

Breast Cancer TNBC - Triple-Negative Breast Cancer HR Positive/HER-2 Negative Breast Cancer HER2 + Breast Cancer Early Stage Breast Cancer

Start date: 2025-10-27
Primary completion: 2032-12-01
Enrollment: 900

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.